TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Who May Qualify: - Has documented diagnosis of hATTR-PN - Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant - Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive) - Has a Karnofsky Performance Status (KPS) of ≥60% Who Should NOT Join This Trial: - Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study - Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis - Has a New York Heart Association (NYHA) heart failure classification \>2 - Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 upper limit of normal (ULN) - Has total bilirubin \>1.5 ULN - Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m\^2 - Has other known causes of sensorimotor or autonomic neuropathy Always talk to your doctor about whether this trial is right for you.